In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE To Lose Cost Watch-dog Status By 2013

Executive Summary

The National Institute for Health and Clinical Excellence (NICE) will likely no longer have any role in drug cost-effectiveness decisions after 2013, according to UK ministers speaking in London on October 25. Instead, a new value-based pricing system will see drug prices set to reflect a product's worth in the first place, without the need for NICE to carry out its assessment once a drug is already available.News of an end to NICE's most controversial activity will be welcomed by the many companies that have seen their products' commercial potential in the UK severely limited by a negative assessment from the cost watchdog - even though details of the alternative, value-based pricing, are far from clear.

You may also be interested in...

UK's New Cancer Drug Fund Might Not Alleviate Regional Access Disparities

The United Kingdom is creating a £600 million Cancer Drugs Fund to improve treatment access but a consultation document on the initiative is doing little to ease concerns about regional disparities in care.

NICE Enough? Watchdog's Basic Approach Is Sound, But More Transparency Is Urged

An independent report into how NICE values medicines concludes that the basis of its cost-effectiveness assessment is sound, but can be improved. And more transparency would help.

Glucagon And Epinephrine Continue To Drive Growth At Amphastar

Amphastar has delivered another successful quarter, bolstered by sales of glucagon and epinephrine, as it prepares to roll out a number of commercially attractive products and complete a significant branded product acquisition.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts